<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04497168</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00146905</org_study_id>
    <secondary_id>1R01AG065246</secondary_id>
    <nct_id>NCT04497168</nct_id>
  </id_info>
  <brief_title>Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease</brief_title>
  <official_title>Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Parkinson disease (PD) trial will test whether 26 months of citalopram, compared to&#xD;
      placebo, can alter the build-up of toxic amyloid-beta plaques in the visuospatial cortex of&#xD;
      the brain linked to visuospatial cognitive impairment in PD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a proof-of-concept Parkinson disease trial aimed at delaying visuospatial&#xD;
      cognitive decline, an important component of Parkinson dementia. In Parkinson disease,&#xD;
      low-range cortical Abeta plaque levels associate with serotonin terminal losses. Multicenter&#xD;
      Parkinson disease observational findings show that selective serotonin reuptake inhibitors&#xD;
      (SSRIs) associate with lower dementia conversion risk and different cerebrospinal fluid&#xD;
      Abeta-42 levels. This study aims to test the hypothesis that citalopram use in Parkinson&#xD;
      disease will reduce visuospatial cortex Abeta plaque accrual, leading to an amelioration of&#xD;
      longitudinal visuospatial cognitive decline linked to Parkinsonian dementia. The study will&#xD;
      test this hypothesis in a randomized placebo-controlled trial of citalopram 20mg daily over&#xD;
      26 months in Parkinson disease subjects (age ≥65) without depression (n=58).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in visuospatial cortex PiB distribution volume ratio (DVR)</measure>
    <time_frame>Baseline to month 26</time_frame>
    <description>PiB PET can assess the density of amyloid-beta plaques in the brain. This imaging method will be used to quantify the amount of change in amyloid-beta plaques levels--measured specifically within the visuospatial cortex--between month 0 and month 26.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Benton Judgement of Line Orientation (JOLO) test score</measure>
    <time_frame>Baseline to month 26</time_frame>
    <description>This is a standardized test with 30 items that is specific for visual spatial cognition. The minimum score is 0, indicating low visual spatial cognition. The maximum score is 30, indicating high visual spatial cognition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Montreal Cognitive Assessment (MoCA) score</measure>
    <time_frame>Baseline to month 26</time_frame>
    <description>This scale evaluates different domains of cognition like attention, orientation, memory, language, visuoconstructional capacities, and lastly, executive functions. MoCA is a 30 point test with lower scores indicating impaired cognition. The maximum score is 30.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Citalopram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo pills</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Citalopram 20mg</intervention_name>
    <description>20mg daily</description>
    <arm_group_label>Citalopram</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo pills</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with a Parkinson Disease (PD) diagnosis based on the United Kingdom&#xD;
             Parkinson's Disease Society Brain Bank Research Center clinical diagnostic criteria&#xD;
&#xD;
          -  Hoehn and Yahr (HY) scores spanning 2.0 to 3.0&#xD;
&#xD;
          -  Parkinson Disease-type rostral-to-caudal patterns of striatal denervation seen on&#xD;
             dopamine DTBZ PET&#xD;
&#xD;
          -  Age 65 years or greater&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of an atypical parkinsonian condition&#xD;
&#xD;
          -  Current use of any antidepressants or serotoninergic drugs or use of such drugs for&#xD;
             &gt;30 days in the preceding year&#xD;
&#xD;
          -  Evidence of a large artery stroke or mass lesion on brain imaging&#xD;
&#xD;
          -  Participants in whom MRI is contraindicated&#xD;
&#xD;
          -  Participants with a life threatening comorbid illness&#xD;
&#xD;
          -  Severe claustrophobia precluding MRI/PET imaging&#xD;
&#xD;
          -  Inability to participate in research procedures involving ionizing radiation&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Participants with active depression as defined by a Geriatric Depression Scale score&#xD;
             of &gt;10 or on the basis of clinical diagnosis by the PI&#xD;
&#xD;
          -  Participants with baseline HY scores &lt;2.0 or ≥3.0&#xD;
&#xD;
          -  Participants with a QTc interval on baseline EKG &gt;0.43 for men or &gt;0.45 for women,&#xD;
             and/or &gt;0.44 for men and &gt;0.46 for women when on study drug/placebo&#xD;
&#xD;
          -  Subjects on medications at baseline that could interact with citalopram&#xD;
&#xD;
          -  Subjects unable to swallow pills&#xD;
&#xD;
          -  Subjects with a previous history of mania, ongoing hepatic impairment or epilepsy&#xD;
&#xD;
          -  Subjects with a known allergy to citalopram or escitalopram&#xD;
&#xD;
          -  Subjects with substantial cognitive impairment or dementia that would prevent them&#xD;
             from providing informed consent&#xD;
&#xD;
          -  Subjects in another ongoing clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vikas Kotagal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vikas Kotagal</last_name>
    <phone>734-647-4331</phone>
    <email>vikaskot@umich.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vikas Kotagal</last_name>
      <phone>734-647-4331</phone>
      <email>vikaskot@umich.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2020</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Vikas Kotagal</investigator_full_name>
    <investigator_title>Assistant Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Serotonin</keyword>
  <keyword>Selective Serotonin Reuptake Inhibitor</keyword>
  <keyword>Amyloid-beta</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Participant data will be uploaded in a timely manner in the Data Management Resource (DMR) of the NIH/NINDS Parkinson's Disease Biomarker Program (PDBP). Biospecimens (DNA) will be banked in the NIA NCRAD biorepository. Uploaded datasets will be stripped of identifiers in order to prevent the possibility of identifying human subjects participants in this study from the publically available dataset.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Consistent with NIA policies, the study team will ensure the dataset is shared by the occurrence of the earlier of the following two milestones: either the date of primary publication or within 9 months of lifting of the data lock.</ipd_time_frame>
    <ipd_access_criteria>Access to the coded dataset that is uploaded to the NINDS PDBP DMR is available to any individual who applies to the NINDS PDBP for data access. This process involves providing a brief description of the intended use of the data to be downloaded but does not place any limitations on the use of the data for commercial purposes. Users are also asked to affirm that they will not attempt to establish the identity of, nor attempt to contact any of the PDBP subjects, their physicians, nor their family members.</ipd_access_criteria>
    <ipd_url>https://pdbp.ninds.nih.gov/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

